Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
10-Q - PMGC Holdings Inc. (0001840563) (Filer)
8-K - PMGC Holdings Inc. (0001840563) (Filer)
8-K - PMGC Holdings Inc. (0001840563) (Filer)
4 - PMGC Holdings Inc. (0001840563) (Issuer)
3/A - PMGC Holdings Inc. (0001840563) (Issuer)
4 - PMGC Holdings Inc. (0001840563) (Issuer)
NEWPORT BEACH, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:PMGC) ("PMGC" or the "Company"), a diversified public holding company executing a targeted roll-up strategy in U.S.-based manufacturing, is pleased to announce that its wholly owned subsidiary, AGA Precision Systems LLC ("AGA Precision Systems" or "AGA"), has completed International Traffic in Arms Regulations (ITAR) registration and is in compliance with ITAR. The ITAR is administered by the U.S. State Department's Directorate of Defense Trade Controls, which controls the export and import of defense articles and services. The ITAR registration further enables AGA to pursue defense and aerospace programs
Strategic Acquisition Accelerates PMGC's U.S. Manufacturing Roll-Up, Expanding Footprint Across Aerospace and Industrial Supply ChainsAcquisition Adds Profitable CNC Platform with Established Customer Relationships to drive earnings scalability and operational synergies NEWPORT BEACH, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:PMGC) ("PMGC" or the "Company"), a diversified public holding company executing a targeted roll-up strategy in U.S.-based manufacturing, today announced that its wholly owned subsidiary, AGA Precision Systems LLC ("AGA"), has acquired all operating assets of Indarg Engineering, Inc., a precision computer numerical control ("CNC") machining
NEWPORT BEACH, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company" or "we"), a diversified public holding company executing a targeted roll-up strategy in U.S.-based manufacturing, today announced that its operating subsidiary AGA Precision Systems LLC ("AGA") has reported a sales backlog of approximately over $711,000 in current orders logged into its Material Requirements Planning system, Sage100. AGA has also confirmed that it is actively bidding on additional Request for Quotations totaling over $700,000 from new customers. PMGC believes AGA's current backlog and pending orders reflect robust demand, underscoring AGA's growth momentum and
NEWPORT BEACH, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the "Company" or "PMGC," "our," or "we") (NASDAQ:ELAB), a diversified holding company, is proud to announce its annual sponsorship of TCA Venture Group's ("TCA") Orange County network for 2025. As a Southern California Network Sponsor, PMGC is actively pursuing investments and M&A opportunities to strengthen its portfolio while fostering local business growth and expanding its market presence. TCA Venture Group (formerly known as Tech Coast Angels) is one of the largest and most active angel investor networks in the United States. With a history spanning over 25 years, TCA has been instrumental in funding early-s
Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme.Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator.Dr. Shirihai is a renowned researcher regularly invited as a keynote speaker at annual scientific conferences and has consulted for Johnson & Johnson, Bayer, AstraZeneca and Pfizer, among other healthcare companies. NEWPORT BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the appointment of Orian Shirihai, MD, PhD, t
NEWPORT BEACH, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. "We are honored to be forming a Scientific Advisory Board with renowned members that possess deep and complementary knowledge in metabolic diseases, obesity, weight management, muscle preservation and physical function in addition to significant experience in clinical
Adds $1.39 Million in Cash-Flow-Positive Revenue from a CNC Machining, Mold Manufacturing, and Specialty Metals Operation Serving the Aerospace, Defense, and Industrial Markets.Adds to PMGC's U.S. Manufacturing Revenue Through a Second Bolt-On Acquisition Under Its Roll-Up Strategy, Bringing Estimated Total Annualized Revenue to Over $2.25 Million. NEWPORT BEACH, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC" or "we"), a diversified public holding company, today announced that it has completed the acquisition of AGA Precision Systems LLC ("AGA"), a California-based CNC machining business that generated over $1.39 million in revenue in 2
Serves over 300 Commercial Clients including Data Centers, Technology Manufacturers and Information Technology (IT) Service Providers.Adds cash flow positive revenue, enhances PMGC's exposure to U.S. semiconductor and artificial intelligence ("AI") infrastructure growth, and marks the launch of its strategic acquisition program targeting U.S. businesses. NEWPORT BEACH, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC," "we," or "us"), a diversified public holding company, today announced that it has completed the acquisition of Pacific Sun Packaging Inc. ("Pacific Sun") a specialized custom IT packaging company based in San Clemente, Califor
Agreement adds two drug candidates to product pipeline consisting of (i) "EL-22", a clinical stage engineered probiotic expressing myostatin, and (ii) "EL-32", a preclinical engineered probiotic expressing dual myostatin & activin-A.Exclusive license covers global rights excluding South Korea.Clinical and preclinical data supports advancing EL-22, a novel investigational myostatin asset for the treatment of obesity for an investigational new drug "IND" application in 2025. EL-22 has demonstrated significant increase in body weight and restored muscle damage in preclinical mouse models, suggesting potential as a combination to glucagon-like peptide-1 "GLP-1" products to treat obesity. NEWPOR
SC 13G - Elevai Labs Inc. (0001840563) (Subject)
SC 13G - Elevai Labs Inc. (0001840563) (Subject)
SC 13G - Elevai Labs Inc. (0001840563) (Subject)